Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
24 Aug 2023
24 Aug 2023
Historique:
received:
19
04
2023
accepted:
17
07
2023
revised:
10
07
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
aheadofprint
Résumé
Management of urinary symptoms in elderly patients with benign prostatic hyperplasia (BPH) is complex given challenges with medications and invasive surgeries. Rezum, a minimally invasive water vapor therapy, is an emerging alternative. We compare real-world Rezum outcomes between young and elderly patients over 4 years. We retrospectively analyzed a multiethnic population treated with Rezum at a single center between 2017-2019. Patients were stratified into young (<65 years) or elderly (≥65 years) cohorts. International Prostate Symptom Score (IPSS), Quality of Life (QoL), maximum urinary flow rate (Qmax), decisional regret scores, and adverse events (AEs) were assessed at baseline, 1-, 3-, 6-, 12-, and/or 48-months. Descriptive statistics were compared using t-tests, Chi-squared, or Mann-Whitney U tests. Changes in outcomes were assessed using Wilcoxon signed-rank tests, stratified by age. 256 patients - 146 (57%) young and 110 (43%) elderly - were included. The majority were Asian (33.2%) or non-Hispanic Black (28.9%). Significant improvements were observed in the combined cohort at 4-years in IPSS, QoL, and Qmax when compared to baseline (all p < 0.05). Between the age cohorts, there were no significant differences in IPSS, QoL, or Qmax at any follow-up. Within both cohorts, significant improvements in IPSS and QoL were found from baseline to all follow-ups. In the young cohort, Qmax was significantly improved from baseline to all follow-ups while in the elderly cohort, this was observed only at the 3-month follow-up. No significant differences in AEs or regret was found between cohorts. There was no significant difference in 4-year surgical retreatment rates between cohorts (elderly 4.0% vs young 4.4%, p = 0.86). There were no significant differences in IPSS, QoL, or AEs between elderly and younger men over 4 years following Rezum, suggesting comparable benefits and risks. Future research is warranted to clarify the impact of Rezum on Qmax in elderly men.
Sections du résumé
BACKGROUND
BACKGROUND
Management of urinary symptoms in elderly patients with benign prostatic hyperplasia (BPH) is complex given challenges with medications and invasive surgeries. Rezum, a minimally invasive water vapor therapy, is an emerging alternative. We compare real-world Rezum outcomes between young and elderly patients over 4 years.
METHODS
METHODS
We retrospectively analyzed a multiethnic population treated with Rezum at a single center between 2017-2019. Patients were stratified into young (<65 years) or elderly (≥65 years) cohorts. International Prostate Symptom Score (IPSS), Quality of Life (QoL), maximum urinary flow rate (Qmax), decisional regret scores, and adverse events (AEs) were assessed at baseline, 1-, 3-, 6-, 12-, and/or 48-months. Descriptive statistics were compared using t-tests, Chi-squared, or Mann-Whitney U tests. Changes in outcomes were assessed using Wilcoxon signed-rank tests, stratified by age.
RESULTS
RESULTS
256 patients - 146 (57%) young and 110 (43%) elderly - were included. The majority were Asian (33.2%) or non-Hispanic Black (28.9%). Significant improvements were observed in the combined cohort at 4-years in IPSS, QoL, and Qmax when compared to baseline (all p < 0.05). Between the age cohorts, there were no significant differences in IPSS, QoL, or Qmax at any follow-up. Within both cohorts, significant improvements in IPSS and QoL were found from baseline to all follow-ups. In the young cohort, Qmax was significantly improved from baseline to all follow-ups while in the elderly cohort, this was observed only at the 3-month follow-up. No significant differences in AEs or regret was found between cohorts. There was no significant difference in 4-year surgical retreatment rates between cohorts (elderly 4.0% vs young 4.4%, p = 0.86).
CONCLUSIONS
CONCLUSIONS
There were no significant differences in IPSS, QoL, or AEs between elderly and younger men over 4 years following Rezum, suggesting comparable benefits and risks. Future research is warranted to clarify the impact of Rezum on Qmax in elderly men.
Identifiants
pubmed: 37620427
doi: 10.1038/s41391-023-00703-0
pii: 10.1038/s41391-023-00703-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in america project: benign prostatic hyperplasia. J Urol. 2008;179:S75–80. https://doi.org/10.1016/j.juro.2008.03.141 .
doi: 10.1016/j.juro.2008.03.141
pubmed: 18405761
Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology. 2006;68:804–9. https://doi.org/10.1016/j.urology.2006.04.019 .
doi: 10.1016/j.urology.2006.04.019
pubmed: 17070357
Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology. 2008;72:318–21. https://doi.org/10.1016/j.urology.2008.03.057 .
doi: 10.1016/j.urology.2008.03.057
pubmed: 18554695
Bortnick E, Brown C, Simma-Chiang V, Kaplan SA. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol. 2020;12:1756287220929486. https://doi.org/10.1177/1756287220929486 .
doi: 10.1177/1756287220929486
pubmed: 32547642
pmcid: 7273551
Leslie SW, Chargui S, Stormont G. Transurethral Resection Of The Prostate. StatPearls. StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.
Westwood J, Geraghty R, Jones P, Rai BP, Somani BK. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol. 2018;10:327–33. https://doi.org/10.1177/1756287218793084 .
doi: 10.1177/1756287218793084
pubmed: 30344644
pmcid: 6180381
Babar M, Loloi J, Tang K, Syed U, Ciatto M. Emerging outcomes of water vapor thermal therapy (Rezum) in a broad range of patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. Low Urin Trac Symptoms. 2022;14:140–54. https://doi.org/10.1111/luts.12435 .
doi: 10.1111/luts.12435
Tadrist A, Baboudjian M, Bah MB, Alegorides C, Bottet F, Arroua F, et al. Water vapor thermal therapy for indwelling urinary catheter removal in frail patients. Int Urol Nephrol. 2023;55:249–53. https://doi.org/10.1007/s11255-022-03408-w .
doi: 10.1007/s11255-022-03408-w
pubmed: 36342555
Eredics K, Wehrberger C, Henning A, Sevcenco S, Marszalek M, Rauchenwald M, et al. Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency. Prostate Cancer Prostatic Dis. 2022;25:302–5. https://doi.org/10.1038/s41391-021-00462-w .
doi: 10.1038/s41391-021-00462-w
pubmed: 34588631
Babar M, Masoud Z, Labagnara K, Loloi J, Sayed R, Singh S, et al. Efficacy and safety of the Rezum system for the treatment of catheter-dependent urinary retention: Three-year real-world outcomes in a multimorbid, multiethnic population. Low Urin Tract Symptoms. 2023. https://doi.org/10.1111/luts.12482 .
Campobasso D, Siena G, Chiodini P, Conti E, Franzoso F, Maruzzi D, et al. Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study. Prostate Cancer Prostatic Dis. 2022. https://doi.org/10.1038/s41391-022-00587-6 .
Higazy A, Osman D, Osman T. Rezum: a novel minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. A review article. Int Urol Nephrol. 2021;53:1747–56. https://doi.org/10.1007/s11255-021-02878-8 .
doi: 10.1007/s11255-021-02878-8
pubmed: 33932221
Gao B, Lu S, Bhojani N, Zorn KC, Chughtai B, Elterman D. Office-based procedures for BPH. Curr Urol Rep. 2021;22:63. https://doi.org/10.1007/s11934-021-01081-7 .
doi: 10.1007/s11934-021-01081-7
pubmed: 34913101
Leong JY, Tokarski AT, Roehrborn CG, Das AK. UroLift and Rezum: minimally invasive surgical therapies for the management of benign prostatic hyperplasia. Can J Urol. 2021;28:2–5.
pubmed: 34453421
Spinos T, Katafigiotis I, Leotsakos I, Grivas N, Zabaftis C, Ermidis D, et al. Rezūm water vapor therapy for the treatment of patients with urinary retention and permanent catheter dependence secondary to benign prostate hyperplasia: a systematic review of the literature. World J Urol. 2023;41:413–20. https://doi.org/10.1007/s00345-022-04258-y .
doi: 10.1007/s00345-022-04258-y
pubmed: 36534152
Siena G, Sessa F, Cindolo L. Use of a Schelin Catheter for analgesia during Rezum treatment of the prostate. Prostate Cancer Prostatic Dis. 2023:1–3. https://doi.org/10.1038/s41391-023-00644-8 .
McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with Benign Prostatic Hyperplasia: 4-year results from randomized controlled study. Urology. 2019;126:171–9. https://doi.org/10.1016/j.urology.2018.12.041 .
doi: 10.1016/j.urology.2018.12.041
pubmed: 30677455
Mooney R, Goldberg K, Wong D, Roehrborn C. Convective radio frequency thermal therapy for treatment of Benign Prostatic Hyperplasia: single office experience with 255 patients over 4 years. Urol Pract. 2020;7:28–33. https://doi.org/10.1097/UPJ.0000000000000061 .
doi: 10.1097/UPJ.0000000000000061
pubmed: 37317411
Cindolo L, Campobasso D, Conti E, Uricchio F, Franzoso F, Maruzzi D, et al. Do patients treated with water vapor therapy and meeting randomized clinical trial criteria have better urinary and sexual outcomes than an unselected cohort? J Endourol. 2023;37:323–9. https://doi.org/10.1089/end.2022.0637 .
doi: 10.1089/end.2022.0637
pubmed: 36453237
Rowaiee R, Akhras A, Lakshmanan J, Sikafi Z, Janahi F. Rezum therapy for Benign Prostatic Hyperplasia: Dubai’s initial experience. Cureus. 2021;13:e18083. https://doi.org/10.7759/cureus.18083 .
doi: 10.7759/cureus.18083
pubmed: 34692298
pmcid: 8523475
Babar M, Loloi J, Azhar U, Tang K, Ines M, Singh S, et al. Rezum outcomes in relationship to number of injections: is less more? J Endourol. 2023;37:157–64. https://doi.org/10.1089/end.2022.0390 .
doi: 10.1089/end.2022.0390
pubmed: 36112665
Aladesuru O, Amankwah K, Elterman D, Zorn K, Bhojani N, Te A, et al. Pilot study of "less is more" Rezum for treatment of BPH. Urology. 2022;165:256–60. https://doi.org/10.1016/j.urology.2022.01.039 .
doi: 10.1016/j.urology.2022.01.039
pubmed: 35139413
Babar M, Azhar U, Loloi J, Sayed R, Labagnara K, Zhu M, et al. Water vapour thermal therapy (Rezum) outcomes at 4 years in relationship to the number of injections: is the ‘less is more’ treatment approach durable? BJU Int. Mar 2023. https://doi.org/10.1111/bju.16017 .
Raizenne BL, Bouhadana D, Zorn KC, Barber N, Gilling P, Kaplan S, et al. Functional and surgical outcomes of Aquablation in elderly men. World J Urol. 2022;40:2515–20. https://doi.org/10.1007/s00345-022-04137-6 .
doi: 10.1007/s00345-022-04137-6
pubmed: 36040501
Campobasso D, Morselli S, Greco F, De Nunzio C, Destefanis P, Fasolis G, et al. Efficacy and safety profile of GreenLight laser photoselective vaporization of the prostate in ≥ 75 years old patients: results from the Italian GreenLight Laser Study Group. Aging Clin Exp Res. 2023;35:877–85. https://doi.org/10.1007/s40520-023-02351-9 .
doi: 10.1007/s40520-023-02351-9
pubmed: 36763245
Bouhadana D, Nguyen DD, Zhang X, Mao J, Elterman D, Te A, et al. Safety and efficacy of TURP vs. laser prostatectomy for the treatment of benign prostatic hyperplasia in multi-morbid and elderly individuals aged ≥ 75. World J Urol. 2021;39:4405–12. https://doi.org/10.1007/s00345-021-03779-2 .
doi: 10.1007/s00345-021-03779-2
pubmed: 34232353